July 18th 2025
The phase 2 Co-PSMA trial enrolled 50 patients with biochemical recurrence of prostate cancer.
GU Tumor Board: Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies
September 27, 2025
Register Now!
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
View More
Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment
View More
Next steps in research for AI prostate cancer mapping
September 20th 2024"[Although] we were very excited about the finding in this study showing that Unfold AI could be superior to MRI in detecting extracapsular disease, our next step is to validate this in a multi-institutional, prospective manner," says Shyam Natarjan, PhD.
PSMA levels linked to tumor biology, treatment sensitivity in treatment-naïve prostate cancer
September 20th 2024“Our findings suggest that high PSMA tumors may respond better to AR-targeting therapies. Tumors with low PSMA possess markers of cancer stem cells and are associated with resistance to radiotherapy," the authors write.
PSMA-PET by PROMISE criteria shows prognostic value across prostate cancer continuum
September 20th 2024“Our PPP nomograms accurately stratify high- vs. low-risk groups for overall survival in early and late stages of prostate cancer and yield better prediction than established clinical risk tools," wrote the authors.
How Unfold AI compares with other AI-based tools in prostate cancer
September 12th 2024“In the period where a patient receives a diagnosis of favorable intermediate-risk cancer or higher and doesn't know what to do, there is a big unmet need/gap that we aim to serve with Unfold AI,” says Shyam Natarajan, PhD.